Compare INSM & HIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSM | HIG |
|---|---|---|
| Founded | 1988 | 1810 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 36.5B |
| IPO Year | 2000 | 1995 |
| Metric | INSM | HIG |
|---|---|---|
| Price | $156.33 | $128.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 23 | 17 |
| Target Price | ★ $188.71 | $148.13 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 02-19-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 1.87% |
| EPS Growth | N/A | ★ 22.54 |
| EPS | N/A | ★ 12.22 |
| Revenue | $447,022,000.00 | ★ $27,917,000,000.00 |
| Revenue This Year | $49.51 | $7.59 |
| Revenue Next Year | $134.47 | $5.65 |
| P/E Ratio | ★ N/A | $10.52 |
| Revenue Growth | ★ 30.34 | 7.03 |
| 52 Week Low | $60.40 | $105.98 |
| 52 Week High | $212.75 | $140.50 |
| Indicator | INSM | HIG |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 32.22 |
| Support Level | $153.19 | $127.88 |
| Resistance Level | $164.62 | $130.64 |
| Average True Range (ATR) | 7.67 | 2.28 |
| MACD | -0.76 | -0.90 |
| Stochastic Oscillator | 9.60 | 8.82 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.